CAPSTONE INVESTMENT ADVISORS, LLC - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 254 filers reported holding BRIDGEBIO PHARMA INC in Q4 2023. The put-call ratio across all filers is 1.26 and the average weighting 0.8%.

Quarter-by-quarter ownership
CAPSTONE INVESTMENT ADVISORS, LLC ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q1 2024$2,583,057
+577.0%
83,540
+477.4%
0.01%
+350.0%
Q3 2023$381,52114,4680.00%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q4 2023
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$60,317,00040.05%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$308,746,0006.20%
M28 Capital Management LP 513,300$5,102,0005.33%
GREAT POINT PARTNERS LLC 1,050,000$10,437,0002.51%
Octagon Capital Advisors LP 933,743$9,281,0001.60%
HHLR ADVISORS, LTD. 5,362,014$53,298,0001.40%
VIKING GLOBAL INVESTORS LP 26,620,991$264,613,0001.22%
Cormorant Asset Management, LP 1,469,179$14,604,0001.02%
Fernwood Investment Management, LLC 204,550$2,033,0000.86%
TANG CAPITAL MANAGEMENT LLC 585,424$5,819,0000.71%
View complete list of BRIDGEBIO PHARMA INC shareholders